Anna Constance Vind

Anna Constance Vind, MSc, PhD

Oxidative stress in obesity-associated liver disease

Non-alcoholic fatty liver disease (NAFLD) affects 1 out of 4 people worldwide. There is no treatment, and its most severe form, non-alcoholic steatohepatitis (NASH), is the most common cause of liver transplantation. Thus, new medical strategies for combating fatty liver diseases are in high demand. A hallmark of fatty liver diseases is hyperactive stress-activated protein kinases (SAPK). These kinases control inflammation and cell death, and are major contributors to disease progression. This project investigates how oxidative stress, a primary by-product of excessive fat metabolism, stimulates SAPK activation and consequently influences NASH development. To address this, we will work with primary cells, mouse models and patient material such as blood samples and liver biopsies. We aim to translate our findings into new clinically-relevant non-invasive biomarkers, and our ultimate goal is to develop the first drug treatment option for NASH patients.


Basic mentor: Professor Simon Bekker-Jensen, Department of Cellular and Molecular Medicine, University of Copenhagen

Clinical mentor: Professor Filip Kragh Knop, Center for Clinical Metabolic Research, Herlev and Gentofte Hospital